A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma
- Conditions
- Lymphoma, Mantle-Cell
- Interventions
- First Posted Date
- 2022-10-03
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 36
- Registration Number
- NCT05564052
- Locations
- 🇹🇷
Ondokuz Mayis University, Atakum, Turkey
🇧🇷Santa Casa de Misericordia de Belo Horizonte, Belo Horizonte, Brazil
🇧🇷Sociedade Beneficente de Senhoras - Hospital Sirio Libanes HSL Unidade Brasilia, Brasilia, Brazil
A Study of Teclistamab in Combination With Daratumumab and Lenalidomide (Tec-DR) and Talquetamab in Combination With Daratumumab and Lenalidomide (Tal-DR) in Participants With Newly Diagnosed Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2022-09-23
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 1590
- Registration Number
- NCT05552222
- Locations
- 🇨🇳
The Second Xiangya Hospital of Central South Hospital, Changsha, China
🇨🇳The First Affliated Hospital Of Nanchang University, Nanchang, China
🇦🇹SCRI CCCIT gem GmbH, Salzburg, Austria
A Study of Aticaprant 10 Milligrams (mg) as Adjunctive Therapy in Adult Participants With MDD With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
- Conditions
- Depressive Disorder, MajorAnhedonia
- Interventions
- Drug: AticaprantOther: Placebo
- First Posted Date
- 2022-09-22
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 710
- Registration Number
- NCT05550532
- Locations
- 🇦🇷
Centro Medico Luquez, Cordoba, Argentina
🇦🇷INSA Instituto de Neurociencias San Agustín, La Plata, Argentina
🇦🇷Clinica Privada de Salud Mental Santa Teresa de Ávila, La Plata, Argentina
A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants
- Conditions
- Healthy
- Interventions
- Drug: PlaceboDrug: JNJ-88260237
- First Posted Date
- 2022-09-15
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 40
- Registration Number
- NCT05541315
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
A Study of Guselkumab Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
- Conditions
- Colitis, Ulcerative
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2025-01-10
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 418
- Registration Number
- NCT05528510
- Locations
- 🇰🇷
Kangbuk Samsung Hospital, Seoul, Korea, Republic of
🇰🇷Severance Hospital Yonsei University Health System, Seoul, Korea, Republic of
🇰🇷Samsung Medical Center, Seoul, Korea, Republic of
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4
- First Posted Date
- 2022-08-31
- Last Posted Date
- 2022-11-23
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 20
- Registration Number
- NCT05522517
- Locations
- 🇧🇪
Clinical Pharmacology Unit, Antwerpen, Belgium
A Study of JNJ-75276617 in Combination With Conventional Chemotherapy for Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias
- Conditions
- Acute LeukemiasAcute Leukemia of Ambiguous LineageAcute Myeloid LeukemiaAcute Lymphoblastic Leukemia
- Interventions
- Drug: JNJ-75276617Drug: FludarabineDrug: CytarabineDrug: Intrathecal ChemotherapyDrug: DexamethasoneDrug: VincristineDrug: Pegaspargase
- First Posted Date
- 2022-08-30
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05521087
- Locations
- 🇺🇸
Memorial Sloan Kettering, New York, New York, United States
🇺🇸University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
- Conditions
- Depressive Disorder, Major
- Interventions
- Drug: Aticaprant
- First Posted Date
- 2022-08-26
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 840
- Registration Number
- NCT05518149
- Locations
- 🇺🇸
University of Alabama at Birmingham - The Kirklin Clinic, Birmingham, Alabama, United States
🇺🇸SW Biomedical Research LLC, Tucson, Arizona, United States
🇺🇸University of Arizona, Tucson, Arizona, United States
Pre-Approval Access Single Patient Request for Talquetamab in Relapsed or Refractory Multiple Myeloma
- Conditions
- Relapsed or Refractory Multiple Myeloma
- First Posted Date
- 2022-08-16
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- Janssen Research & Development, LLC
- Registration Number
- NCT05503550
- Locations
- 🇸🇮
DUMMY, Dummy, Slovenia
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
- Conditions
- Carcinoma, Non-small-Cell Lung
- Interventions
- Drug: AmivantamabDrug: LazertinibDrug: CarboplatinDrug: Direct Oral Anticoagulant (DOAC)Drug: PemetrexedDrug: Low Molecular Weight Heparin (LMWH)
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2025-01-09
- Lead Sponsor
- Janssen Research & Development, LLC
- Target Recruit Count
- 390
- Registration Number
- NCT05498428
- Locations
- 🇧🇷
Associacao Hospitalar Moinhos de Vento, Porto Alegre, Brazil
🇧🇷Instituto D Or de Pesquisa e Ensino IDOR, Salvador, Brazil
🇧🇷Hospital Alemao Oswaldo Cruz, Sao Paulo, Brazil